Partial breast brachytherapy as the primary treatment for breast cancer diagnosed after mantle radiation therapy for hodgkin's disease

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 2, 2009, Pages 132-136

  Chadha, Manjeet ^a,b   Yoon, Harold ^a   Feldman, Sheldon ^b   Shah, Niral ^a   Moore, Eric ^a   Harrison, Louis B ^a  

^a Department of Radiation Oncology ^*

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Breast cancer; Hodgkin's disease; Lumpectomy; Partial breast irradiation

Indexed keywords

ANTIBIOTIC AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BACITRACIN; IRIDIUM 192;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER RECURRENCE; CANCER RELAPSE; CATHETER INFECTION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERSTITIAL RADIATION; LYMPH NODE DISSECTION; MANTLE FIELD RADIOTHERAPY; PARTIAL MASTECTOMY; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; SENTINEL LYMPH NODE; TUMOR VOLUME;

ADULT; BRACHYTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HODGKIN DISEASE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 67749088537     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318180c880     Document Type: Article

References (49)

1. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85:25-31.
2. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745-751.
3. Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996;87:3625-3632.
4. Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 1997;79:1203-1210.
5. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol. 1998;16:338-347.
6. Gervais-Fagnou DD, Girouard C, Laperriere N, et al. Breast cancer in women following supradiaphragmatic irradiation for Hodgkin's disease. Oncology. 1999;57:224-231.
7. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000;26:291-302.
8. Metayer C, Lynch CF, Clarke A, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435-2443.
9. Wolden SL, Hancock SL, Carlson RW, et al. Management of breast cancer after Hodgkin's disease. J Clin Oncol. 2000;18:765-772.
10. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95:971-980.
11. Wahner-Roedler DL, Nelson DF, Croghan IT, et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphagmatic radiation for Hodgkin lymphoma: mayo clinic experience. Mayo Clin Proc. 2003;78:708-715.
12. Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasm among 1641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five northern countries. J Clin Oncol. 1996;14:1442-1446.
13. Winchester DP, Cox JD. Standards for diagnosis and management of invasive breast carcinoma. American College of Radiotherapy, American College of Surgeons, College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin. 1998;48:83-107.
14. Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol. 1992;10:1674-1681.
15. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Breast radiotherapy after breast-conserving surgery. CMAJ. 1998;158(suppl. 3):S35-S42.
16. Vicini FA, Chen PY, Fraile M, et al. Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast conserving therapy: preliminary results of a pilot trial. Int J Radiat Oncol Biol Phys. 1997;38:301-310.
17. Kuske RR Jr. Breast brachytherapy. Hematol Oncol Clin North Am. 1999; 13:543-558.
18. Baglan KL, Martinez AA, Frazier RC, et al. The use of high dose-rate brachytherapy alone after lumpectomy in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2001;50:1003-1011.
19. Nag S, Kuske RR, Vicini FA, et al. Brachytherapy in the treatment of breast cancer. Oncology. 2001;15:195-202.
20. Vicini FA, Baglan K, Kestin L, et al. The emerging role of brachytherapy in the management of patients with breast cancer. Semin Radiat Oncol. 2002; 12:31-39.
21. Benitez PR, Chen PY, Vicini FA, et al. Partial breast irradiation in breast conserving therapy by way of interstitial brachytherapy. Am J Surg. 2004; 188:355-364.
22. Polgar C, Major T, Fodor J, et al. High-dose rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys. 2004;60:1173-1181.
23. Wallner P, Arthur D, Bartelink H, et al. Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD,. December 8- 10, 2002. J Natl Cancer Inst. 2004;96:175-184.
24. Chen PY, Vicini FA, Benitez P, et al. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation. Cancer. 2006;106:991-999.
25. Ott OJ, Hildebrandt G, Potter R, et al. Accelerated partial breast irradiation with multi-catheter brachytherapy: local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiother Oncol. 2007;82:281-286.
26. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109 -122.
27. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three- dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491-500.
28. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose escalation study using 3-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005;103:2118-2127.
29. Chadha M, Feldman S, Boolbol S, et al. 53 Phase I/II study of partial breast brachytherapy in patients who have previously received external beam radiation therapy (RT) to the breast. Int J Radiat Oncol Biol Phys. 2006;66:S31.
30. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. Available at: http://ctep.cancer.gov/reporting/ctc-v30.html. Accessed March 31, 2003.
31. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484-3494.
32. Zellmer DL, Wilson JF, Janjan NA. Dosimetry of the breast for determining carcinogenic risk in mantle irradiation. Int J Radiat Oncol Biol Phys. 1991; 21:1343-1351.
33. Christie DR, Wills R, Drew JF, et al. The doses received by the breast during mantle radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:223-226.
34. Kowalski A, Smith S. Measurement of radiation dose delivered to breast tissue during mantle field irradiation for Hodgkin's disease. Med Dosim. 1998;23:31-36.
35. Boice JD Jr, Land CE, Shore RE, et al. Risk of breast cancer following low-dose radiation exposure. Radiology. 1979;131:539-597.
36. Hall E, Wu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56:83-88.
37. Preston DL, Mattsson A, Holmberg E, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220 -235.
38. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182-192.
39. Tinger A, Wasserman TH, Klein EE, et al. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys. 1997;37:865-870.
40. Arthur DW, Winter K, Kuske RR, et al. A phase II trial of brachytherapy alone following lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys. 2006;66: S29 -S30. (suppl; abstr 51).
41. National Surgical Adjuvant Breast and Bowel Project B-39/Radiation Therapy Oncology Group 0413 Protocol. Available at: http://www.rtog.org/members/ protocols/0413/0413.pdf.
42. Intra M, Gentilini O, Veronesi P, et al. A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT). Breast Cancer Res. 2005;7:R828-R832.
43. Intra M, Gatti G, Luini A, et al. Surgical technique of intraoperative radiotherapy in conservative treatment of limited-stage breast cancer. Arch Surg. 2002;137:737-740.
44. Cutuli B, Borel C, Dhermain F, et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol. 2001;59:247-255.
45. Aref I, Cross P. Conservative surgery and radiation therapy for early stage breast cancer after previous mantle radiation for Hodgkin's disease. Br J Radiol. 2000;73:905-906.
46. Deutsch M, Gerszten K, Bloomer W, et al. Lumpectomy and breast irradiation for breast cancer arising after previous radiotherapy for Hodgkin's disease. Am J Clin Oncol. 2001;24:33-34.
47. Engel J, Kerr J, Schlesinger-Raab A, et al. Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. Breast J. 2004;10:223-231.
48. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004;96:376-387.
49. van Leeuwen FE, Klokman WJ, van't Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487-497.